New Drug Offers Hope for Pancreatic Cancer Patients

Cancer accounts for nearly one in six deaths globally, totalling around 10 million annually. While survival rates for some cancers like melanoma exceed 90%, pancreatic cancer remains challenging, with only 5% survival after five years. A new drug, daraxonrasib, shows promise by doubling survival time in trials, offering hope for patients with this difficult disease.

Read the full story at The Guardian AU→